Publications by authors named "Mikaela Bankston"
Disease Site Specialization in the Academic Radiation Oncology Workforce: Evidence of Gender Differences.
Int J Radiat Oncol Biol Phys
November 2024
Article Synopsis
- The study investigates gender representation in radiation oncology (RO), finding that only 30.5% of ARO faculty are women and highlighting significant gender disparities in disease site specialization.
- Women are primarily concentrated in treating breast and gynecologic cancers, with over 40% representation, while specialties like genitourinary and thoracic cancers have less than 25% female faculty.
- The findings suggest that women faculty are more likely to treat certain cancers compared to men, pointing to a need for further research on the reasons behind these gender-based specialization trends.
Factors associated with complex oral treatment device usage in patients with head and neck cancer.
Clin Transl Radiat Oncol
September 2021
Purpose: The objective was to identify clinical and epidemiological factors associated with utilization of a complex oral treatment device (COTD), which may decrease toxicity in patients undergoing radiation therapy for head and neck cancer (HNC).
Materials And Methods: We retrospectively reviewed data from 1992 to 2013 in the Surveillance, Epidemiology, and End Results (SEER)-Medicare databases to analyze COTD usage during intensity-modulated radiation therapy (IMRT) for patients diagnosed with cancer of the tongue, floor of mouth, nasopharynx, tonsil, or oropharynx. Patients with a radiation simulation and complex treatment device code within 4 weeks before the first IMRT claim were identified as meeting COTD usage criteria.
Article Synopsis
- - The study examined the impact of cell-of-origin (COO), MYC, and Bcl-2 overexpression in 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) who received radiation therapy after responding to immunochemotherapy.
- - Over a median follow-up of 31.1 months, there were only 4 relapses, and the cohort showed high three-year survival rates: 95% progression-free survival (PFS), 96% overall survival (OS), and 100% loco-regional relapse-free survival (LRFS).
- - The results indicated that outcomes did not differ based on COO or MYC/Bcl-2 expression, and consolidative radiation therapy effectively controlled local
Importance: Response-adapted randomized trials have used positron emission tomography-computed tomography to attempt to identify patients with early-stage favorable Hodgkin lymphoma (ESFHL) who could be treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) without radiation therapy (RT). While maximal efficacy is demonstrated with combined modality therapy, RT is often omitted in fear of late adverse effects; however, the application of modern RT could limit these toxic effects.
Objective: To determine the radiation doses delivered to organs at risk with modern involved-site RT among patients with ESFHL treated with 20 Gy after 2 cycles of ABVD.